SWTX
Price:
$30.94
Market Cap:
$2.30B
SpringWorks Therapeutics, Inc. acquires, develops, and commercializes medicines for underserved patient populations suffering from rare diseases and cancer. Its lead product candidate is nirogacestat, an oral small molecule gamma secretase inhibitor that is in Phase III clinical trial for the treatment of desmoid tumors. The company is also developing mirdametinib, an oral small molecule MEK inhibitor that is in Phase 2b clinical trials for the treatment of neurofibromatosis type 1-associated plexiform neurofibromas, as well as Phase 1/2a clinical trial for the treatment of NF1-PN; mirdametinib + lifirafenib, a combination therapy that is in Phase 1b/2 clinical trial in patients with advance...[Read more]
Industry
Biotechnology
IPO Date
2019-09-13
Stock Exchange
NASDAQ
Ticker
SWTX
According to SpringWorks Therapeutics, Inc.’s latest financial reports and current stock price. The company's current ROE is -56.13%. This represents a change of 288.83% compared to the average of -14.44% of the last 4 quarters.
The mean historical ROE of SpringWorks Therapeutics, Inc. over the last ten years is 28.42%. The current -56.13% ROE has changed -297.53% with respect to the historical average. Over the past ten years (40 quarters), SWTX's ROE was at its highest in in the December 2018 quarter at 32.11%. The ROE was at its lowest in in the March 2018 quarter at -33.19%.
Average
28.42%
Median
-7.94%
Minimum
-51.92%
Maximum
176.72%
Discovering the peaks and valleys of SpringWorks Therapeutics, Inc. ROE, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.
Maximum Annual Increase = 416.30%
Maximum Annual ROE = 176.72%
Minimum Annual Increase = -217.31%
Minimum Annual ROE = -51.92%
Year | ROE | Change |
---|---|---|
2023 | -51.92% | -207.92% |
2022 | 48.10% | -217.31% |
2021 | -41.01% | 416.30% |
2020 | -7.94% | -53.29% |
2019 | -17.00% | -118.49% |
2018 | 91.97% | -47.96% |
The current ROE of SpringWorks Therapeutics, Inc. (SWTX) is greater than its 3-year, greater than its 5-year, and less than than its 10-year historical averages
3-year avg
-14.94%
5-year avg
-13.95%
10-year avg
28.42%
SpringWorks Therapeutics, Inc.’s ROE is greater than Relay Therapeutics, Inc. (-43.66%), greater than Stoke Therapeutics, Inc. (-57.89%), greater than Pliant Therapeutics, Inc. (-41.05%), greater than Black Diamond Therapeutics, Inc. (-69.08%), greater than Arvinas, Inc. (-50.26%), greater than Day One Biopharmaceuticals, Inc. (-22.40%), greater than Mirati Therapeutics, Inc. (-81.10%), greater than Amylyx Pharmaceuticals, Inc. (-46.15%), greater than Terns Pharmaceuticals, Inc. (-39.58%), greater than Apellis Pharmaceuticals, Inc. (-139.02%), greater than TCR2 Therapeutics Inc. (-89.51%), greater than Revolution Medicines, Inc. (-34.57%), greater than Atreca, Inc. (-195.22%), greater than Passage Bio, Inc. (-70.73%), greater than Cerevel Therapeutics Holdings, Inc. (-98.94%), greater than Avidity Biosciences, Inc. (-32.89%), greater than Blueprint Medicines Corporation (-47.66%), greater than Sana Biotechnology, Inc. (-71.60%), greater than Kymera Therapeutics, Inc. (-24.96%), greater than Monte Rosa Therapeutics, Inc. (-70.40%),
Company | ROE | Market cap |
---|---|---|
-43.66% | $950.40M | |
-57.89% | $689.69M | |
-41.05% | $881.01M | |
-69.08% | $168.95M | |
-50.26% | $1.84B | |
-22.40% | $1.49B | |
-81.10% | $4.12B | |
-46.15% | $388.07M | |
-39.58% | $599.50M | |
-139.02% | $3.48B | |
-89.51% | $58.11M | |
-34.57% | $9.33B | |
-195.22% | $3.57M | |
-70.73% | $37.34M | |
-98.94% | $8.19B | |
-32.89% | $5.25B | |
-47.66% | $5.84B | |
-71.60% | $836.47M | |
-24.96% | $3.05B | |
-70.40% | $542.54M |
One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like SpringWorks Therapeutics, Inc. using the financials and key metrics that matter to you in a single view.
The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:
Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.
Get your free trial here.
The easiest way to analyze a company like SpringWorks Therapeutics, Inc. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.
Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.
Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.
What is the ROE?
How can you use the ROE?
What is SpringWorks Therapeutics, Inc.'s ROE?
How is the ROE calculated for SpringWorks Therapeutics, Inc. (SWTX)?
What is the highest ROE for SpringWorks Therapeutics, Inc. (SWTX)?
What is the 3-year average ROE for SpringWorks Therapeutics, Inc. (SWTX)?
What is the 5-year average ROE for SpringWorks Therapeutics, Inc. (SWTX)?
How does the current ROE for SpringWorks Therapeutics, Inc. (SWTX) compare to its historical average?